#

+1 (917) 893 7512

  • #
  • #
  • #
#
The US Rosacea Market Report, US Rosacea Market: Size, Trends & Forecasts (2018-2022)

The US Rosacea Market: Size, Trends & Forecasts (2018-2022)

Publish Date:Jan 2018
No. of Pages:56

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report titled “The US Rosacea Market: Size, Trends & Forecasts (20018-2022)”, provides a detailed analysis of the US rosacea market with market sizing and growth pattern. The analysis includes rosacea market in terms of value, number of patients; number of patients seeking treatment and market share by segments. It also provides analysis of the US dermatology drugs market in terms of value and market share by segments.

Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the US rosacea market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Foamix Pharmaceuticals Ltd., Bayer Group, Galderma and Valeant Pharmaceuticals International are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.

Company Coverage

Foamix Pharmaceuticals Ltd.
Bayer Group
Galderma
Valeant Pharmaceuticals International

Executive Summary

Rosacea is a common chronic condition of the skin with a high prevalence rate among the US population. It is observed that it naturally begins at any time after the age of 30 and more and mostly affect the area of nose, cheeks and forehead. In some cases, rosacea may also occur on the neck, chest, scalp or ears. Rosacea symptoms and signs include facial flushing, fine red vascular lines, swollen, red eyelids and many more. The disease is more common in women and those who have fair skin. The cause of such skin condition is still unknown and cannot be cured. The only way to control rosacea is by minimizing its symptoms.

The US rosacea market has grown over the past few years and is anticipated to grow during the forecasted period also i.e. 2018-2022 at a high growth rate on the back of rising incidence rate of the disease among the US population.

The growth in the market will be driven by aging population, unhealthy eating habits and environmental factors, rising disposable income and entry of new drugs and treatments in the market. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.

1. Executive Summary

2. Introduction

2.1 Overview of Rosacea
2.1.1 Symptoms of Rosacea
2.1.2 Causes of Rosacea
2.1.3 Types of Rosacea

3. Market Analysis

3.1 The US Dermatology Drugs Market Analysis
3.1.1 The US Dermatology Drugs Market by Value
3.1.2 The US Dermatology Drugs Market by Segments 

3.2 The US Rosacea Market Analysis
3.2.1 The US Rosacea Market by Value
3.2.2 The US Rosacea Market by Number of Patients
3.2.3 The US Rosacea Market by Number of Patients Seeking Treatment
3.2.4 The US Rosacea Market by Segments
3.2.5 The US Rosacea Market Top Brands by Value
3.2.6 The US Rosacea Market Top Brands by Volume

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Unhealthy Eating Habits and Environmental Factors
4.1.2 High Prevalence Rate of Rosacea
4.1.3 Aging Population
4.1.4 Rising Disposable Personal Income

4.2 Challenges
4.2.1 Lack of Awareness
4.2.2 Stringent Government Regulations

4.3 Market Trends
4.3.1 Approval of New Drugs

5. Competitive Landscape

5.1 The US Rosacea Market by Players/Drugs 
5.2 The US Rosacea Drugs Competitive Landscape

6. Company Profiles

6.1 Foamix Pharmaceuticals Ltd.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Bayer Group
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Galderma
6.3.1 Business Overview
6.3.2 Financial Overview

6.4 Valeant Pharmaceuticals International
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Figure 1: Types of Rosacea
Figure 2: The US Dermatology Drugs Market by Value; 2014-2017 (US$ Billion)
Figure 3: The US Dermatology Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 4: The US Dermatology Drugs Market by Segments; 2016
Figure 5: The US Rosacea Market by Value; 2016-2017 (US$ Billion)
Figure 6: The US Rosacea Market by Value; 2018-2022E (US$ Billion)
Figure 7: The US Rosacea Market by Number of Patients; 2016-2017 (Million)
Figure 8: The US Rosacea Market by Number of Patients; 2018-2022E (Million)
Figure 9: The US Rosacea Market by Number of Patients Seeking Treatment;2017-2022E (Million)
Figure 10: The US Rosacea Market by Segments; 2016
Figure 11: Share of Old Age Population (65 years and Older) in the Total US Population; 1990-2020 (%)
Figure 12: The US Disposable Personal Income; 2013-2017 (US$ Trillion)
Figure 13: The US Rosacea Market by Players/Drugs; 2016
Figure 14: Foamix Pharmaceuticals Ltd. Revenues; 2012-2016 (US$ Million)
Figure 15: Bayer Group Revenues; 2012-2016 (US$ Billion)
Figure 16: Bayer Group Revenue by Segments; 2016
Figure 17: Bayer Group Revenue by Geography; 2016
Figure 18: Valeant Pharmaceuticals Revenue; 2012-2016 (US$ Billion)
Figure 19: Valeant Pharmaceuticals Revenue by Segments; 2016
Table 1: The US Rosacea Market Top Brands by Value; 2016
Table 2: The US Rosacea Market Top Brands by Volume; 2016
Table 3: The US Rosacea Drugs Competitive Landscape
Table 4: Product Candidate Pipeline
Table 5: Finacea (FMX103) related Events (Completed and Anticipated)